The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma
- Author
- BRUNELLO, Eleonora3 ; BOGINA, Giuseppe2 ; MANFRIN, Erminia1 ; IBRAHIM, Merdol5 6 ; MILLER, Keith6 ; TORTORA, Giampaolo3 ; MOLINO, Annamaria3 ; JASANI, Bharat7 ; BECCARI, Serena1 ; BONETTI, Franco1 ; CHILOSI, Marco1 ; MARTIGNONI, Guido1 ; BRIA, Emilio1 ; BRUNELLI, Matteo1 ; VERGINE, Marco4 ; ZAMBONI, Giuseppe1 2 ; PEDRON, Serena1 ; DANIELE, Isabella1 ; FURLANETTO, Jenny3 ; CARBOGNIN, Luisa3 ; MARCONI, Marcella2
[1] Department of Pathology and Diagnostic, University of Verona, P.le Scuro n. 10, 37134 Verona, Italy
[2] SacroCuore Hospital, Negrar, Verona, Italy
[3] Medical Oncology dU, University of Verona, AOUI, Verona, Italy
[4] Royal Sussex County Hospital-Brighton and Sussex University Hospitals, NHS Trust, Brighton, United Kingdom
[5] Department of Pathology, University College London, London, United Kingdom
[6] UKNeqas, United Kingdom National External Quality Assessment Service, London, United Kingdom
[7] Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Ireland - Source
Journal of cancer research and clinical oncology. 2013, Vol 139, Num 9, pp 1563-1568, 6 p ; ref : 3/4 p
- CODEN
- JCROD7
- ISSN
- 0171-5216
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Her-2/neu gene amplification In situ hybridization Trastuzumab Triple negative breast carcinoma
- Keyword (fr)
- Amplification génique Anticancéreux Gène erbB2 Gène onc cellulaire Homme Inhibiteur Protooncogène Trastuzumab Anti-HER2 Cancer du sein triple négatif Hybridation in situ Récepteur HER2 Anticorps monoclonal Cancer Pathologie de la glande mammaire Pathologie du sein Tumeur maligne
- Keyword (en)
- Gene amplification Antineoplastic agent erbB2 Gene C-Onc gene Human Inhibitor Protooncogene Trastuzumab Triple negative breast cancer In situ hybridization Human Epidermal growth factor Receptor 2 Monoclonal antibody Cancer Mammary gland diseases Breast disease Malignant tumor
- Keyword (es)
- Amplificación génica Anticanceroso Gen erbB2 Gen onc celular Hombre Inhibidor Protooncogen Trastuzumab Cáncer de pecho triple negativo Hibridación in situ Anticuerpo monoclonal Cáncer Glándula mamaria patología Seno patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27632683
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00432-013-1479-0 
https://dx.doi.org/10.1007/s00432-013-1479-0
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Journal of cancer research and clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:26:\"J. cancer res. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"139\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1563\";s:8:\"\u0000*\u0000epage\";s:4:\"1568\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-5216\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BRUNELLO\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Eleonora\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"BOGINA, Giuseppe\";i:1;s:16:\"MANFRIN, Erminia\";i:2;s:15:\"IBRAHIM, Merdol\";i:3;s:13:\"MILLER, Keith\";i:4;s:18:\"TORTORA, Giampaolo\";i:5;s:17:\"MOLINO, Annamaria\";i:6;s:14:\"JASANI, Bharat\";i:7;s:15:\"BECCARI, Serena\";i:8;s:15:\"BONETTI, Franco\";i:9;s:14:\"CHILOSI, Marco\";i:10;s:17:\"MARTIGNONI, Guido\";i:11;s:12:\"BRIA, Emilio\";i:12;s:16:\"BRUNELLI, Matteo\";i:13;s:14:\"VERGINE, Marco\";i:14;s:17:\"ZAMBONI, Giuseppe\";i:15;s:14:\"PEDRON, Serena\";i:16;s:17:\"DANIELE, Isabella\";i:17;s:17:\"FURLANETTO, Jenny\";i:18;s:16:\"CARBOGNIN, Luisa\";i:19;s:17:\"MARCONI, Marcella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCROD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Journal of cancer research and clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:26:\"J. cancer res. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"139\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1563\";s:8:\"\u0000*\u0000epage\";s:4:\"1568\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-5216\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BRUNELLO\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Eleonora\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"BOGINA, Giuseppe\";i:1;s:16:\"MANFRIN, Erminia\";i:2;s:15:\"IBRAHIM, Merdol\";i:3;s:13:\"MILLER, Keith\";i:4;s:18:\"TORTORA, Giampaolo\";i:5;s:17:\"MOLINO, Annamaria\";i:6;s:14:\"JASANI, Bharat\";i:7;s:15:\"BECCARI, Serena\";i:8;s:15:\"BONETTI, Franco\";i:9;s:14:\"CHILOSI, Marco\";i:10;s:17:\"MARTIGNONI, Guido\";i:11;s:12:\"BRIA, Emilio\";i:12;s:16:\"BRUNELLI, Matteo\";i:13;s:14:\"VERGINE, Marco\";i:14;s:17:\"ZAMBONI, Giuseppe\";i:15;s:14:\"PEDRON, Serena\";i:16;s:17:\"DANIELE, Isabella\";i:17;s:17:\"FURLANETTO, Jenny\";i:18;s:16:\"CARBOGNIN, Luisa\";i:19;s:17:\"MARCONI, Marcella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCROD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Journal of cancer research and clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:26:\"J. cancer res. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"139\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1563\";s:8:\"\u0000*\u0000epage\";s:4:\"1568\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-5216\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BRUNELLO\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Eleonora\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"BOGINA, Giuseppe\";i:1;s:16:\"MANFRIN, Erminia\";i:2;s:15:\"IBRAHIM, Merdol\";i:3;s:13:\"MILLER, Keith\";i:4;s:18:\"TORTORA, Giampaolo\";i:5;s:17:\"MOLINO, Annamaria\";i:6;s:14:\"JASANI, Bharat\";i:7;s:15:\"BECCARI, Serena\";i:8;s:15:\"BONETTI, Franco\";i:9;s:14:\"CHILOSI, Marco\";i:10;s:17:\"MARTIGNONI, Guido\";i:11;s:12:\"BRIA, Emilio\";i:12;s:16:\"BRUNELLI, Matteo\";i:13;s:14:\"VERGINE, Marco\";i:14;s:17:\"ZAMBONI, Giuseppe\";i:15;s:14:\"PEDRON, Serena\";i:16;s:17:\"DANIELE, Isabella\";i:17;s:17:\"FURLANETTO, Jenny\";i:18;s:16:\"CARBOGNIN, Luisa\";i:19;s:17:\"MARCONI, Marcella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCROD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Journal of cancer research and clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:26:\"J. cancer res. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"139\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1563\";s:8:\"\u0000*\u0000epage\";s:4:\"1568\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-5216\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BRUNELLO\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Eleonora\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"BOGINA, Giuseppe\";i:1;s:16:\"MANFRIN, Erminia\";i:2;s:15:\"IBRAHIM, Merdol\";i:3;s:13:\"MILLER, Keith\";i:4;s:18:\"TORTORA, Giampaolo\";i:5;s:17:\"MOLINO, Annamaria\";i:6;s:14:\"JASANI, Bharat\";i:7;s:15:\"BECCARI, Serena\";i:8;s:15:\"BONETTI, Franco\";i:9;s:14:\"CHILOSI, Marco\";i:10;s:17:\"MARTIGNONI, Guido\";i:11;s:12:\"BRIA, Emilio\";i:12;s:16:\"BRUNELLI, Matteo\";i:13;s:14:\"VERGINE, Marco\";i:14;s:17:\"ZAMBONI, Giuseppe\";i:15;s:14:\"PEDRON, Serena\";i:16;s:17:\"DANIELE, Isabella\";i:17;s:17:\"FURLANETTO, Jenny\";i:18;s:16:\"CARBOGNIN, Luisa\";i:19;s:17:\"MARCONI, Marcella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCROD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00432-013-1479-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Journal of cancer research and clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:26:\"J. cancer res. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"139\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1563\";s:8:\"\u0000*\u0000epage\";s:4:\"1568\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-5216\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BRUNELLO\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Eleonora\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"BOGINA, Giuseppe\";i:1;s:16:\"MANFRIN, Erminia\";i:2;s:15:\"IBRAHIM, Merdol\";i:3;s:13:\"MILLER, Keith\";i:4;s:18:\"TORTORA, Giampaolo\";i:5;s:17:\"MOLINO, Annamaria\";i:6;s:14:\"JASANI, Bharat\";i:7;s:15:\"BECCARI, Serena\";i:8;s:15:\"BONETTI, Franco\";i:9;s:14:\"CHILOSI, Marco\";i:10;s:17:\"MARTIGNONI, Guido\";i:11;s:12:\"BRIA, Emilio\";i:12;s:16:\"BRUNELLI, Matteo\";i:13;s:14:\"VERGINE, Marco\";i:14;s:17:\"ZAMBONI, Giuseppe\";i:15;s:14:\"PEDRON, Serena\";i:16;s:17:\"DANIELE, Isabella\";i:17;s:17:\"FURLANETTO, Jenny\";i:18;s:16:\"CARBOGNIN, Luisa\";i:19;s:17:\"MARCONI, Marcella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCROD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
